Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
Amgen on Wednesday announced that its phase 3 study involving ABP 959, a biosimilar candidate to eculizumab (Soliris), had met its primary endpoints in the DAHLIA study. The biosimilar is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other indications.
In its statement, Amgen said that “ABP 959 has the same pharmaceutical form, dosage strength, route of administration, and dosing regimen” as the approved eculizumab in both the United States and the European Union.
Detailed results of this study will be presented at a future medical congress and submitted for publication.
PNH is a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis. This life-threatening disease brings about intravascular hemolytic anemia, bone marrow failure, and thromboembolic episodes. Patients experience arterial and venous thromboembolic episodes, visceral organ damage, rapid deterioration in quality of life, and increased mortality. Eculizumab is a monoclonal antibody that works by binding to a complementary protein to halt the mechanism that drive these effects.
DAHLIA was a phase 3, randomized, double-blind, active-controlled, 2-period crossover study in adult patients with PNH treated with eculizumab for at least 6 months. Patients were randomized 1:1 to receive the biosimilar or reference product in 1 of 2 sequences: (1) the biosimilar was given first, every 14 days for 52 weeks, followed by the reference product, every 14 days for 52 weeks; or (2) treatment followed the same schedule, except the reference product was given first. In the second treatment period, the switch occurred after 26 weeks, at week 79.
Results showed there as no clinically meaningful differences between ABP 959 and Soliris, based on control of intravascular hemolysis and measures of effectiveness at predefined time points, including when patients were switched from one product to the other.
“The safety and immunogenicity profile of ABP 959 was comparable to Soliris,” Amgen said in the statement.
"Today's positive results with ABP 959 demonstrate similar efficacy, safety and immunogenicity as the reference product, further highlighting Amgen's commitment to providing patients with access to high-quality, biologic therapies," said David M. Reese, MD, executive vice president of Research and Development at Amgen. "We look forward to working with regulators to make this potential biosimilar option available to patients."
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.